Reactivation-related events after HBsAg seroclearance were rare in this population-based cohort. These findings suggest that HBsAg seroclearance may not necessarily indicate complete viral eradication and that careful long-term monitoring may be warranted, particularly in patients with advanced liver disease.
Yamasaki et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: